NCT06883084Enrolling by invitation
Clinical Relevance of Pathologic Regression IN Lymph Node for Locally Advanced Rectal Cancer
Clinical Relevance of the Pathologic Regression in Lymph Node for Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy: A Multi-center Study
Source: ClinicalTrials.gov · Last updated 19 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
We evaluated all related clinical and pathologic data of patients with Locally Advanced Rectal Cancer following Neoadjuvant Chemoradiotherapy, including the pathologic regression grading in the primary tumor site and lymph node, and other histopathologic characteristics. Finally, the present study was aimed at (1) clarifying the clinical significance of the Major Pathologic Regression for Locally Advanced Rectal Cancer following Locally Advanced Rectal Cancer in the primary tumor site and lymph node, and (2) comparing different Neoadjuvant Chemoradiotherapy treatments of this uncommon disease through conducting a large, multi-center cohort study.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 1080 (estimated)
- First submitted
- 12 Mar 2025
- Start date
- 30 Jan 2014
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- Yanhong Deng
- Diseases
- Colorectal cancer
- NCT number
- NCT06883084
What you commit to
- Study type: Observational
- Planned participants: 1080
- From 30 Jan 2014 to the primary completion date, 30 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- distant Metastatic disease at diagnosis. Incomplete clinical or pathologic records.
Who the study is looking for
- \- Adults (≥18 years) diagnosed with locally advanced rectal adenocarcinoma (clinical stage II-III).
- Completion of NCRT followed by curative-intent surgery. Availability of pre- and post-treatment histopathologic data, including standardized regression grading and digitized whole-slide images (WSIs).
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.